Cargando…

Comparative Efficacy and Safety of Antidiabetic Drug Regimens Added to Metformin Monotherapy in Patients with Type 2 Diabetes: A Network Meta-Analysis

INTRODUCTION: When first line therapy with metformin is insufficient for patients with type 2 diabetes (T2D), the optimal adjunctive therapy is unclear. We assessed the efficacy and safety of adjunctive antidiabetic agents in patients with inadequately controlled T2D on metformin alone. MATERIALS AN...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mearns, Elizabeth S., Sobieraj, Diana M., White, C. Michael, Saulsberry, Whitney J., Kohn, Christine G., Doleh, Yunes, Zaccaro, Eric, Coleman, Craig I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412636/ https://www.ncbi.nlm.nih.gov/pubmed/25919293 http://dx.doi.org/10.1371/journal.pone.0125879

Ejemplares similares

Comparative evaluation of incretin‐based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure
por: Nauck, Michael A, et al.
Publicado: (2010)

Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study
por: Chung, Yoo-Ri, et al.
Publicado: (2019)

Comparison of the Efficacy of Glimepiride, Metformin, and Rosiglitazone Monotherapy in Korean Drug-Naïve Type 2 Diabetic Patients: The Practical Evidence of Antidiabetic Monotherapy Study
por: Yoon, Kun Ho, et al.
Publicado: (2011)

Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary
por: Jermendy, György, et al.
Publicado: (2008)

Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis
por: Zhuang, Yan, et al.
Publicado: (2020)

Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis
por: Qian, Dan, et al.
Publicado: (2018)

Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review
por: Aly, Abdalla, et al.
Publicado: (2020)

Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study
por: Roumie, Christianne L., et al.
Publicado: (2017)

Treatment patterns and outcomes in pancreatic cancer: Retrospective claims analysis
por: Doleh, Yunes, et al.
Publicado: (2020)

Cancer risk in patients aged 30 years and above with type 2 diabetes receiving antidiabetic monotherapy: a cohort study using metformin as the comparator
por: Chen, Yu-Ching, et al.
Publicado: (2015)

Response: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8)
por: Chung, Yoo-Ri, et al.
Publicado: (2019)

Letter: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8)
por: Moon, Jun Sung
Publicado: (2019)

Secondary Failure of Metformin Monotherapy in Clinical Practice
por: Brown, Jonathan B., et al.
Publicado: (2010)

A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy
por: White, Judith L, et al.
Publicado: (2014)

Comparison of Antidiabetic Regimens in Patients with Type 2 Diabetes Uncontrolled by Combination Therapy of Sulfonylurea and Metformin: Results of the MOHAS Disease Registry in Korea
por: Choi, Sung Hee, et al.
Publicado: (2017)

Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus()
por: Qiu, Rong, et al.
Publicado: (2014)

What Is the Optimal Monotherapy in Korean Drug-Naïve Type 2 Diabetic Patients?: The Practical Evidence of Antidiabetic Monotherapy Study
por: Choi, Ji Hun, et al.
Publicado: (2011)

Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome
por: Cheng, Lan, et al.
Publicado: (2021)

Predictors of metformin monotherapy failure in gestational diabetes mellitus
por: Benido Silva, Vânia, et al.
Publicado: (2022)

Rapid Acting Insulin Use and Persistence among Elderly Type 2 Diabetes Patients Adding RAI to Oral Antidiabetes Drug Regimens
por: Sambamoorthi, Usha, et al.
Publicado: (2016)

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
por: Fouqueray, Pascale, et al.
Publicado: (2013)

Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression
por: Mearns, Elizabeth S, et al.
Publicado: (2014)

Uncovering antiobesity-related hypertension targets and mechanisms of metformin, an antidiabetic medication
por: Yang, Lu, et al.
Publicado: (2021)

The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
por: DeFronzo, Ralph A., et al.
Publicado: (2009)

Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus
por: Seino, Yutaka, et al.
Publicado: (2015)

Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial
por: Ferreira-Hermosillo, Aldo, et al.
Publicado: (2020)

Lamivudine monotherapy as a holding regimen for HIV-positive children
por: Patten, Gabriela, et al.
Publicado: (2018)

ANTIDIABETIC EFFECT OF COMBINED AQUEOUS LEAF EXTRACT OF VERNONIA AMYGDALINA AND METFORMIN IN RATS
por: Michael, U. Adikwu, et al.
Publicado: (2010)

The Antidiabetic Drug Metformin Inhibits the Proliferation of Bladder Cancer Cells in Vitro and in Vivo
por: Zhang, Tao, et al.
Publicado: (2013)

Regulatory Effects of Metformin, an Antidiabetic Biguanide Drug, on the Metabolism of Primary Rat Adipocytes
por: Szkudelski, Tomasz, et al.
Publicado: (2022)

Research: Treatment Study to determine the durability of glycaemic control with early treatment with a vildagliptin–metformin combination regimen vs. standard-of-care metformin monotherapy—the VERIFY trial: a randomized double-blind trial
por: Del Prato, S, et al.
Publicado: (2014)

Safety, tolerability, and efficacy of metformin extended-release oral antidiabetic therapy in patients with type 2 diabetes: An observational trial in Asia
por: Kim, Chul-Hee, et al.
Publicado: (2012)

Metformin Monotherapy Downregulates Diabetes-Associated Inflammatory Status and Impacts on Mortality
por: Tizazu, Anteneh Mehari, et al.
Publicado: (2019)

Secondary metformin monotherapy failure in individuals with type 2 diabetes mellitus
por: Weiss, Tracey, et al.
Publicado: (2021)

Trends in add-on medications following metformin monotherapy for type 2 diabetes
por: Swart, Elizabeth CS, et al.
Publicado: (2022)

Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia
por: Ji, Linong, et al.
Publicado: (2019)

Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus
por: Jeon, Ja Young, et al.
Publicado: (2021)

Cardiovascular outcomes and safety with antidiabetic drugs
por: Aldossari, Khaled K.
Publicado: (2018)

Efficacy and Cardiovascular Safety of Antidiabetic Medications
por: Pappachan, Joseph M.
Publicado: (2021)

Efficacy and Safety of Metformin Versus the Other Oral Antidiabetic Drugs in Japanese Type 2 Diabetes Patients: A Network Meta-analysis
por: Nishimura, Rimei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_disbcio5hhve4hi9hro9d4begf